Does tumoral (111)In-ibritumomab accumulation correlate with therapeutic effect and outcome in relapsed or refractory low-grade B-cell lymphoma patients undergoing (90)Y-ibritumomab radioimmunotherapy?

Objectives The aim of this study was to determine whether tumoral 111In-ibritumomab accumulation on pre-treatment imaging correlates with therapeutic responses and progression-free survival (PFS) in patients with non-Hodgkin’s lymphoma (NHL) undergoing 90Y-ibritumomab radioimmunotherapy (RIT).